Cancer Family
Adnexal Neoplasm
CI-CAN-00000005Explore in graph →
Non-malignant777 active trials5 approved drugs94 evidence items
- NCIt
- C212119
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000005Explore in graph →
Clinical trials
3,522 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06879353 | Comparison of Single-Dose Tranexamic Acid Vs. Placebo in Ovarian Cancer Surgery | completed | N/A | 372 | Sheikh Zayed Medical CollegeOTHER_GOV | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02098343 | p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 | completed | Phase 1 / Phase 2 | 247 | Aprea TherapeuticsINDUSTRY | 8 | Mar 17, 2025 | clinicaltrials |
| NCT02489903 | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | completed | Phase 2 | 139 | EpicentRx, Inc.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT03268382 | p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 | completed | Phase 2 | 36 | Aprea TherapeuticsINDUSTRY | 3 | Mar 17, 2025 | clinicaltrials |
| NCT03206047 | Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04330040 | Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer(SOLI) | completed | Phase 4 | 202 | AstraZenecaINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT05697198 | PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine(PREFER) | completed | — | 1,429 | Labcorp Corporation of America Holdings, IncINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT06853730 | Regional Distribution Mapping of Lymph Node Metastasis in Epithelial Ovarian Cancer | completed | — | 654 | Xu HuishanOTHER | 0 | Mar 3, 2025 | clinicaltrials |
| NCT04870177 | Study of AK112 in the Treatment of Advanced Gynecological Tumors | completed | Phase 2 | 53 | AkesoINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04517357 | A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients | completed | Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT01220154 | Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer | completed | Phase 1 | 9 | David O'MalleyOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT01314105 | BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer | completed | Phase 1 | 19 | Boehringer IngelheimINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03552471 | Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | Phase 1 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT02891824 | ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab(ATALANTE) | completed | Phase 3 | 614 | ARCAGY/ GINECO GROUPOTHER | 7 | Feb 11, 2025 | clinicaltrials |
| NCT04805333 | Phase 1 Dose Escalation of ArtemiCoffee | completed | Phase 1 | 13 | Frederick R. Ueland, M.D.OTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT00753545 | Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer | completed | Phase 2 | 265 | AstraZenecaINDUSTRY | 17 | Feb 3, 2025 | clinicaltrials |
| NCT04492007 | Feasibility Testing of Patient Reported Outcomes - Informed Symptom Management System (PRISMS)(PRISMS) | completed | N/A | 46 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT04406623 | Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer | completed | Phase 1 | 27 | Shattuck Labs, Inc.INDUSTRY | 1 | Jan 30, 2025 | clinicaltrials |
| NCT05887531 | Abdominopelvic Cancer Prehabilitation | completed | N/A | 66 | Universitat Jaume IOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06798610 | The Impact of the Inflammation Index on Predicting Postoperative Complications in Ovarian Cancer | completed | — | 228 | Sakarya UniversityOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT05995860 | Study of a Rapid Triadic Communication Intention Elicitation Intervention to Improve Supportive Oncology Care Delivery(PRECursOr) | completed | N/A | 47 | Indiana UniversityOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT03154190 | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer | completed | N/A | 128 | Stanford UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT05633836 | MicroFluO: FLUorescence-guided Surgery for Ovarian Cancer(MicroFluO) | completed | N/A | 3 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT03532139 | Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study) | completed | Phase 2 | 24 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT04703920 | Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer | completed | Phase 1 | 26 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06787170 | Prediction of Platinum Resistance and Prognosis of High-grade Serous Ovarian Cancer(PPRPHGSOC) | completed | — | 1,129 | The First People's Hospital of YunnanOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06789224 | Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device(REMOVE) | completed | N/A | 136 | Lindis Bloodcare GmbHINDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT03994653 | Cancer Loyalty Card Study(CLOCS) | completed | — | 963 | Imperial College LondonOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT03667716 | COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. | completed | Phase 1 | 121 | Compugen LtdINDUSTRY | 1 | Jan 17, 2025 | clinicaltrials |
| NCT05256576 | KORE-INNOVATION: a Prospective, Multi-site Clinical Trial to Implement and Analyse the Effects of an Innovative Perioperative Care Pathway to Reduce Complications for Patients with Ovarian Cancer(KORE) | completed | N/A | 465 | Charite University, Berlin, GermanyOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT03314740 | Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib(BAROCCO) | completed | Phase 2 | 123 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT05904730 | Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations | completed | Phase 1 | 10 | Lynkcell EuropeOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT00715819 | Use of Otoscope as a Non-invasive Tool for Diagnosis of Pilomatricoma | completed | — | 4 | Stanford UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 79 | Famewave Ltd.INDUSTRY | 3 | Dec 27, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT00170573 | Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer | completed | Phase 2 | 77 | North Eastern German Society of Gynaecological OncologyOTHER | 0 | Dec 16, 2024 | clinicaltrials |
| NCT02042430 | Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Early Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 13, 2024 | clinicaltrials |
| NCT03752216 | NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.(NiQoLe) | completed | Phase 4 | 141 | ARCAGY/ GINECO GROUPOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT04589039 | A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South Korea | completed | — | 662 | TakedaINDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT02312245 | Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 13 | Mayo ClinicOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT02054351 | Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)(OVAR) | completed | Phase 1 | 42 | Ganymed Pharmaceuticals GmbHINDUSTRY | 2 | Nov 21, 2024 | clinicaltrials |
| NCT03159572 | Homologous Recombination Inquiry Through Ovarian Malignancy Investigations(HITOMI) | completed | — | 996 | Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT00889382 | A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) | completed | Phase 1 / Phase 2 | 152 | Astellas Pharma IncINDUSTRY | 10 | Nov 20, 2024 | clinicaltrials |
| NCT06697613 | Development and Validation of a Prediction Model for AKI Following Cisplatin-Based HIPEC in Patients With Ovarian Cancer | completed | — | 150 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT02953457 | Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation | completed | Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03225989 | Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer | completed | Phase 1 / Phase 2 | 47 | Lokon Pharma ABINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | completed | Phase 1 / Phase 2 | 26 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT04227522 | Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients(MAMOC) | completed | Phase 3 | 42 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT04525183 | REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue | completed | N/A | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 15, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 19, 2025source: clinicaltrials